Evommune (EVMN) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evommune is the larger company by market cap ($225.7 million vs $222.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | KROS |
|---|---|---|
| Share price | $6.22 | $11.21 |
| Market cap | $225.74M | $222.26M |
| 1-day change | -5.90% | +1.82% |
| YTD return | -63.67% | -44.94% |
| 1-year return | — | -28.37% |
| 5-year return | — | -71.25% |
| EPS (TTM) | $-3.75 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $22.55 |
| 52-week low | $6.08 | $9.69 |
| Distance from 52-week high | -81.27% | -50.29% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +287.94% | +76.90% |
| Average volume | 675.52K | 197.68K |
| Shares outstanding | 36.29M | 19.83M |
| Employees | 48 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 48 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Healthcare · Biotechnology · 92 employees
EVMN vs KROS FAQ
Which is bigger, Evommune or Keros Therapeutics?
Evommune (EVMN) is larger, with a market capitalization of $225.74M compared with $222.26M for Keros Therapeutics (KROS).
Are Evommune and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.